Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 26 professional analysts, the 12-month price target for Alnylam Pharmaceuticals stock ranges from a low of $220 to a high of $570. The average analyst price target of $401.92 forecasts a -7.07% decrease in the stock price over the next year.

Price Target: $401.92 (-7.07%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$220	$401.92	$400	$570
Change	-49.14%	-7.07%	-7.52%	+31.79%

Analyst Ratings

The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	11	11	11	11	13	13
Buy	9	9	9	8	8	10
Hold	3	3	3	3	3	4
Sell	1	1	1	1	1	0
Strong Sell	0	0	0	0	0	0
Total	24	24	24	23	25	27

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Trucchio HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $500 → $570	Strong Buy	Maintains	$500 → $570	+31.79%	Aug 7, 2025
Jessica Fye JP Morgan	JP Morgan	Buy Maintains $348 → $475	Buy	Maintains	$348 → $475	+9.82%	Aug 6, 2025
Leland Gershell Oppenheimer	Oppenheimer	Hold → Buy Upgrades $490	Hold → Buy	Upgrades	$490	+13.29%	Aug 4, 2025
Andy Chen Wolfe Research	Wolfe Research	Sell → Hold Upgrades n/a	Sell → Hold	Upgrades	n/a	n/a	Aug 4, 2025
Greg Harrison Scotiabank	Scotiabank	Buy Maintains $342 → $450	Buy	Maintains	$342 → $450	+4.04%	Aug 1, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

3.01B

Increased by 33.75%

from 2.25B

Revenue Next Year

3.96B

Increased by 31.66%

from 3.01B

EPS This Year

-1.39

from -2.18

EPS Next Year

1.47

from -1.39

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	492.85M	844.29M	1.04B	1.83B	2.25B	3.01B	3.96B	5.02B
Revenue Growth	124.28%	71.31%	22.88%	76.24%	22.97%	33.75%	31.66%	26.88%
EPS	-7.46	-7.20	-9.30	-3.52	-2.18	-1.39	1.47	6.36
EPS Growth	-	-	-	-	-	-	-	332.10%
Forward PE	-	-	-	-	-	-	293.65	67.96
No. Analysts	-	-	-	-	-	36	35	27

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	3.6B	5.9B	6.9B
Avg	3.0B	4.0B	5.0B
Low	2.4B	2.8B	3.5B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	59.4%	96.2%	75.4%
Avg	33.7%	31.7%	26.9%
Low	7.9%	-8.3%	-10.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.45	5.52	11.66
Avg	-1.39	1.47	6.36
Low	-2.29	-3.11	1.48

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	691.3%
Avg	-	-	332.1%
Low	-	-	0.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.